Belzutifan Cuts Tumor Procedures in Von Hippel-Lindau Patients

A claims-data study of 237 adults links the drug to a sharp drop in procedures to remove or treat VHL-associated tumors.

Updated on Nov. 20, 2026 in Cancer

Belzutifan Cuts Tumor Procedures in Von Hippel-Lindau Patients

A study analyzing administrative claims data found that belzutifan more than halves the rate of tumor reduction procedures in adult patients with Von Hippel-Lindau disease. The analysis covered 237 patients who first filled a prescription on or after August 2021.

Why it matters

Von Hippel-Lindau disease causes recurring tumors that often require repeated surgical or laser treatment, so a drug that lowers procedure rates could reduce the burden on patients. The findings add real-world evidence to the FDA's August 2021 approval of belzutifan for VHL-associated tumors.

The figures come from a pre- and post-treatment comparison of claims data for 237 adults, showing an adjusted incidence rate ratio of 0.42 for tumor reduction procedures. Long-term effects beyond the 21.9-month median follow-up remain unknown.

The players

Belzutifan

An oral HIF-2α inhibitor approved by the FDA for treating tumors associated with Von Hippel-Lindau disease.

The details

Researchers compared procedure rates per person-month in the 24 months before and after patients started belzutifan, using generalized linear mixed random effects models to account for differences between patients. Of patients remaining on the drug at 24 months, 60.1% stayed on therapy, and 46.4% of those who took a break restarted after a median of 4.7 months.

Timeline

  1. August 13, 2021: The FDA approved belzutifan for adult VHL-associated renal cell carcinoma, CNS hemangioblastomas, and pancreatic neuroendocrine tumors not requiring immediate surgery.

  2. January 2016 to September 2025: The period of claims data analyzed in the study.

  3. November 19-21, 2026: The findings were presented at IKCS: North America 2026 in Dallas, Texas.

Health Landscape

The study builds on the FDA's August 2021 approval of belzutifan, extending its clinical profile with real-world data on how often patients still needed tumor procedures. It shows how post-approval evidence can refine understanding of a drug's effect beyond the trial setting.

For patients with VHL disease, the findings suggest belzutifan may reduce how often they need surgery or laser treatment for tumors. Patients considering the drug should discuss its side effects and treatment-break patterns with their physicians.

The takeaway

Real-world data can show whether a drug's benefits hold up beyond clinical trials. For VHL patients, fewer procedures could mean less disruption to daily life, though long-term results are still being studied.

Further reading

For more on tumor treatments, explore Cancer coverage on Wisevoter.

Source note: This article includes information reported by Cancer Therapy Advisor.